Ting-Yuan David Cheng1, Xiaoling Song2, Shirley A A Beresford2, Gloria Y F Ho3,4, Karen C Johnson5, Mridul Datta6, Rowan T Chlebowski7, Jean Wactawski-Wende8, Lihong Qi9, Marian L Neuhouser2. 1. Department of Epidemiology, University of Florida, 2004 Mowry Road, 4th Floor, RM4213, P. O. Box 100231, Gainesville, FL, 32610, USA. tingyuan.cheng@ufl.edu. 2. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Feinstein Institute for Medical Research, Manhasset, NY, USA. 4. Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA. 5. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. 6. Department of Nutrition Science, Purdue University, West Lafayette, IN, USA. 7. City of Hope National Medical Center, Duarte, CA, USA. 8. Department of Epidemiology and Environment Health, University at Buffalo, The State University of New York, Buffalo, NY, USA. 9. Division of Biostatistics, Department of Public Health Sciences, University of California-Davis, Davis, CA, USA.
Abstract
PURPOSE: Vitamin D has been implicated in lowering lung cancer risk, but serological data on the association among never-smoking women are limited. We report results examining the association of serum 25-hydroxyvitamin D [25(OH)D] concentrations with lung cancer risk among female never smokers. We also examined whether the association was modified by vitamin D supplementation and serum vitamin A concentrations. METHODS: In the Women's Health Initiative, including the calcium/vitamin D (CaD) Trial, we selected 298 incident cases [191 non-small cell lung cancer (NSCLC) including 170 adenocarcinoma] and 298 matched controls of never smokers. Baseline serum 25(OH)D was assayed by a chemiluminescent method. Logistic regression was used to estimate odds ratios (ORs) for quartiles and predefined clinical cutoffs of serum 25(OH)D concentrations. RESULTS: Comparing quartiles 4 versus 1 of serum 25(OH)D concentrations, ORs were 1.06 [95% confidence interval (CI) 0.61-1.84] for all lung cancer, 0.94 (95% CI 0.52-1.69) for NSCLC, and 0.91 (95% CI 0.49-1.68) for adenocarcinoma. Comparing serum 25(OH)D ≥ 75 (high) versus <30 nmol/L (deficient), ORs were 0.76 (95% CI 0.31-1.84) for all lung cancer, 0.71 (95% CI 0.27-1.86) for NSCLC, and 0.81 (95% CI 0.31-2.14) for adenocarcinoma. There is suggestive evidence that CaD supplementation (1 g calcium + 400 IU D3/day) and a high level of circulating vitamin A may modify the associations of 25(OH)D with lung cancer overall and subtypes (p interaction <0.10). CONCLUSIONS: In this group of never-smoking postmenopausal women, the results did not support the hypothesis of an association between serum 25(OH)D and lung cancer risk.
PURPOSE:Vitamin D has been implicated in lowering lung cancer risk, but serological data on the association among never-smoking women are limited. We report results examining the association of serum 25-hydroxyvitamin D [25(OH)D] concentrations with lung cancer risk among female never smokers. We also examined whether the association was modified by vitamin D supplementation and serum vitamin A concentrations. METHODS: In the Women's Health Initiative, including the calcium/vitamin D (CaD) Trial, we selected 298 incident cases [191 non-small cell lung cancer (NSCLC) including 170 adenocarcinoma] and 298 matched controls of never smokers. Baseline serum 25(OH)D was assayed by a chemiluminescent method. Logistic regression was used to estimate odds ratios (ORs) for quartiles and predefined clinical cutoffs of serum 25(OH)D concentrations. RESULTS: Comparing quartiles 4 versus 1 of serum 25(OH)D concentrations, ORs were 1.06 [95% confidence interval (CI) 0.61-1.84] for all lung cancer, 0.94 (95% CI 0.52-1.69) for NSCLC, and 0.91 (95% CI 0.49-1.68) for adenocarcinoma. Comparing serum 25(OH)D ≥ 75 (high) versus <30 nmol/L (deficient), ORs were 0.76 (95% CI 0.31-1.84) for all lung cancer, 0.71 (95% CI 0.27-1.86) for NSCLC, and 0.81 (95% CI 0.31-2.14) for adenocarcinoma. There is suggestive evidence that CaD supplementation (1 g calcium + 400 IU D3/day) and a high level of circulating vitamin A may modify the associations of 25(OH)D with lung cancer overall and subtypes (p interaction <0.10). CONCLUSIONS: In this group of never-smoking postmenopausal women, the results did not support the hypothesis of an association between serum 25(OH)D and lung cancer risk.
Entities:
Keywords:
25-Hydroxyvitamin D; Histology; Lung cancer; Never smokers; Postmenopausal women
Authors: J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Jennifer E Meng; Kathleen M Hovey; Jean Wactawski-Wende; Christopher A Andrews; Michael J Lamonte; Ronald L Horst; Robert J Genco; Amy E Millen Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-04-20 Impact factor: 4.254
Authors: Ting-Yuan David Cheng; Susanna M Cramb; Peter D Baade; Danny R Youlden; Chukwumere Nwogu; Mary E Reid Journal: J Thorac Oncol Date: 2016-06-27 Impact factor: 15.609
Authors: Peter F Schnatz; Xuezhi Jiang; Sharon Vila-Wright; Aaron K Aragaki; Matthew Nudy; David M O'Sullivan; Rebecca Jackson; Erin LeBlanc; Jennifer G Robinson; James M Shikany; Catherine R Womack; Lisa W Martin; Marian L Neuhouser; Mara Z Vitolins; Yiqing Song; Stephen Kritchevsky; JoAnn E Manson Journal: Menopause Date: 2014-08 Impact factor: 2.953
Authors: José M Ordóñez-Mena; Ben Schöttker; Ulrike Haug; Heiko Müller; Josef Köhrle; Lutz Schomburg; Bernd Holleczek; Hermann Brenner Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Yuen Y E Wong; Zoë Hyde; Kieran A McCaul; Bu B Yeap; Jonathan Golledge; Graeme J Hankey; Leon Flicker Journal: PLoS One Date: 2014-06-20 Impact factor: 3.240